FierceBiotechOriginal article
{"a":[{"_":"Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials","$":{"href":"/biotech/slate-uses-fulcrum-vault-nasdaq-245m-migraine-trials","hreflang":"en"}}]}
IPO/OfferingPositive
AI Analysis
Summary
Slate Medicines is pursuing a Nasdaq listing through a reverse merger with Fulcrum Therapeutics, securing $245M in financing to advance clinical trials for its migraine treatment candidate. The transaction occurs six months after Slate exited stealth mode and ahead of clinical data readout for its lead program.
Outcome Details
Reverse merger with Fulcrum Therapeutics to facilitate Nasdaq listing
Importance:7/10
Sentiment:
0.70
IPOreverse mergermigraineclinical developmentfinancing
Related Companies
Read the original article
Published by FierceBiotech on August 17, 2026 9:31 AM